scholarly journals Gene Expression of Glucose Transporter 1 (GLUT1), Hexokinase 1 and Hexokinase 2 in Gastroenteropancreatic Neuroendocrine Tumors: Correlation with F-18-fluorodeoxyglucose Positron Emission Tomography and Cellular Proliferation

Diagnostics ◽  
2013 ◽  
Vol 3 (4) ◽  
pp. 372-384 ◽  
Author(s):  
Tina Binderup ◽  
Ulrich Knigge ◽  
Birgitte Federspiel ◽  
Peter Sommer ◽  
Jane Hasselby ◽  
...  
Keyword(s):  
Gene Expression ◽  
Positron Emission Tomography ◽  
Cellular Proliferation ◽  
Glucose Transporter ◽  
Emission Tomography ◽  
Fluorodeoxyglucose Positron Emission Tomography ◽  
Gastroenteropancreatic Neuroendocrine Tumors ◽  
Glucose Transporter 1 ◽  
Positron Emission ◽  
Fluorodeoxyglucose Positron Emission

scholarly journals F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma

Blood ◽  
2009 ◽  
Vol 114 (10) ◽  
pp. 2068-2076 ◽  
Author(s):  
Twyla B. Bartel ◽  
Jeff Haessler ◽  
Tracy L. Y. Brown ◽  
John D. Shaughnessy ◽  
Frits van Rhee ◽  
...  
Keyword(s):  
Gene Expression ◽  
Positron Emission Tomography ◽  
Multiple Myeloma ◽  
High Risk ◽  
Expression Profiling ◽  
Imaging Techniques ◽  
Emission Tomography ◽  
Fluorodeoxyglucose Positron Emission Tomography ◽  
Positron Emission ◽  
Fluorodeoxyglucose Positron Emission

Abstract F18-fluorodeoxyglucose positron emission tomography (FDG-PET) is a powerful tool to investigate the role of tumor metabolic activity and its suppression by therapy for cancer survival. As part of Total Therapy 3 for newly diagnosed multiple myeloma, metastatic bone survey, magnetic resonance imaging, and FDG-PET scanning were evaluated in 239 untreated patients. All 3 imaging techniques showed correlations with prognostically relevant baseline parameters: the number of focal lesions (FLs), especially when FDG-avid by PET-computed tomography, was positively linked to high levels of β-2-microglobulin, C-reactive protein, and lactate dehydrogenase; among gene expression profiling parameters, high-risk and proliferation-related parameters were positively and low-bone-disease molecular subtype inversely correlated with FL. The presence of more than 3 FDG-avid FLs, related to fundamental features of myeloma biology and genomics, was the leading independent parameter associated with inferior overall and event-free survival. Complete FDG suppression in FL before first transplantation conferred significantly better outcomes and was only opposed by gene expression profiling-defined high-risk status, which together accounted for approximately 50% of survival variability (R2 test). Our results provide a rationale for testing the hypothesis that myeloma survival can be improved by altering treatment in patients in whom FDG suppression cannot be achieved after induction therapy.

Sign in / Sign up

Export Citation Format

Share Document